Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

ArriVent BioPharma Shares Rally 26% in 4 Days Since Other

ArriVent BioPharma Reports 68% Response Rate in Phase 1b NSCLC Trial Publication

+26.59% in 4 days $16.66 when we broke this story → $21.09 at 3:44 PM ET, 23 Oct 2026

ArriVent BioPharma announced the publication of clinical data in the journal Cancer Cell showcasing the efficacy of firmonertinib in treating advanced EGFR PACC-mutant non-small cell lung cancer. The Phase 1b FURTHER trial results, demonstrating high response rates and prolonged progression-free survival, provide the clinical foundation for the ongoing global Phase 3 ALPACCA trial.

Epidemic, coronavirus, lurking, stay home. Stock photo illustrating ArriVent BioPharma's other story.
ArriVent BioPharma, Inc. · Healthcare · Photo: Syaibatulhamdi / Pixabay

Key highlights

  • Confirmed overall response rate of 68% observed at the 240 mg dose level
  • Median progression-free survival reached 16.0 months for the 240 mg cohort
  • Intracranial activity demonstrated by a 47% confirmed response rate in brain metastases
  • Complete molecular response achieved by 80% of evaluable patients by the third treatment cycle
  • Safety profile remained manageable and consistent with previous clinical study observations

Clinical Trial Outcomes

ArriVent BioPharma publicized peer-reviewed results from its FURTHER Phase 1b trial (FURMO-002) in the medical journal Cancer Cell. The study evaluated firmonertinib, an oral EGFR inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) harboring PACC mutations. Data indicated a confirmed overall response rate of 68% and a median progression-free survival of 16.0 months at the 240 mg dose. These findings emphasize the potential for firmonertinib as a targeted, chemotherapy-free treatment for a subset of lung cancer that accounts for approximately 12% of EGFR-mutant tumors, a population currently lacking an established targeted standard of care.

Pipeline and Strategic Significance

  • Provides clinical validation for the ongoing global Phase 3 ALPACCA trial (FURMO-006)
  • Demonstrates enhanced in vitro potency compared to current treatments like osimertinib for PACC mutations
  • Confirms high brain penetrability with meaningful intracranial activity in 41% of patients with baseline metastases
  • Establishes ctDNA clearance as a viable molecular correlate for positive clinical outcomes
  • Supports the development of firmonertinib as a first-line treatment for locally advanced or metastatic disease

Financial and Market Context

The clinical update arrives during a period of significant volatility for ArriVent, with the stock price declining 39.75% over the past month. This downward movement followed an October 6 announcement that the Phase 3 FURVENT trial missed its primary endpoint. Despite market pressure, ArriVent maintains a robust liquidity position, reporting $373.1 million in cash and investments as of June 30, 2026. Management expects these reserves to fund operations into 2028. Currently, the company is trading with an RSI of 25.8, while continuing to advance other pipeline assets, including its novel tetravalent antibody-drug conjugate ARR-002.

ArriVent BioPharma, Inc. share price · last month
Line chart of ArriVent BioPharma, Inc.'s share price over the last month, from $17.94 on 19 Oct → $11.56 on 16 Nov; our story on 19 Oct at $16.66.

Down 30.6% since our story on 19 Oct: $16.66 when we broke it → $11.56 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$17.94
20 Oct$18.85
21 Oct$19.12
22 Oct$19.20
23 Oct$21.00
26 Oct$15.36
27 Oct$15.40
28 Oct$15.73
29 Oct$15.95
30 Oct$14.87
2 Nov$13.35
3 Nov$13.02
4 Nov$13.49
5 Nov$12.23
6 Nov$13.64
9 Nov$14.16
10 Nov$13.49
11 Nov$13.51
12 Nov$13.07
13 Nov$13.01
16 Nov$11.56

Management Perspective

“We believe firmonertinib has the potential to change the treatment paradigm for EGFR PACC-mutant NSCLC, and these findings give us a strong foundation for our global Phase 3 ALPACCA trial.”

Bing Yao, Ph.D., CEO of ArriVent
Earlier announcements by ArriVent BioPharma, Inc.
DateAnnouncementAmount
12 Oct 2026Dosing of first patient in Phase 1 clinical trial of novel tetravalent ADC ARR-002Source: ir.arrivent.com–
06 Oct 2026Phase 3 FURVENT trial of firmonertinib missed primary endpoint of progression-free survivalSource: ir.arrivent.com–
12 Aug 2026Second quarter 2026 financial results and pipeline progress reportedSource: ir.arrivent.com–
07 May 2026U.S. FDA IND clearance received for novel tetravalent ADC ARR-002Source: ir.arrivent.com–
22 Dec 2025First patient dosed in global pivotal Phase 3 ALPACCA trial of firmonertinibSource: ir.arrivent.com–
01 Jul 2025Pricing of underwritten public offering of common stock and pre-funded warrantsSource: lw.com$75.0 Million

Management commentary

“The publication demonstrated that firmonertinib’s unique molecular structure fits the EGFR PACC mutations very well, so this TKI has a unique potential high anti-tumor activity for this lung cancer patient population.”

Xiuning Le, MD, Ph.D., Associate professor at the University of Texas MD Anderson Cancer Center

“We continue to enroll patients in our global Phase 3 ALPACCA trial as we seek to address this area of high unmet medical need where there is no current standard of care.”

Bing Yao, Ph.D., CEO of ArriVent
ArriVent BioPharma, Inc. · financial snapshot
Share price$16.66
Market cap$821M
1-month price change-39.75%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by ArriVent BioPharma announcing the publication of Phase 1b clinical results for firmonertinib in Cancer Cell.

Read the filing ↗
All ArriVent BioPharma, Inc. filings and newsView all →

Track ArriVent BioPharma, Inc. live

Get the next ArriVent BioPharma, Inc. SEC filing seconds after it lands.

More from ArriVent BioPharma, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.